Agoracom Blog Home
Posts Tagged ‘#smallcapstocks’
INTERVIEW: $HPQ.ca Discusses MOU with Big Data Enterprise #Blockchain Solution Developer to Develop a Carbon Credit Marketplace for #Solar Carbon Credits $FSLR $SPWR $CSIQ $NEP
Posted by
at 6:32 PM on Wednesday, April 4th, 2018
New Age Metals $NAM.ca Signs a Binding Letter of Intent (LOI) with Prominent Alaskan Geological Consulting Firm $WG.ca $XTM.ca $WM.ca
Posted by
at 9:55 AM on Wednesday, April 4th, 2018
- Alaska has an extensive mineral inventory and is one of the leading states in America for mineral exploration and development.
- New Age Metals (NAM) objective is to acquire Platinum Group Metals (PGM), PGM Polymetallic, and Rare Metal Projects in Alaska and has signed a binding Letter of Intent (LOI) with Avalon Development Corp., a prominent Alaskan geological consulting firm.
- Avalon Development Corp. is a private company and a leader in mineral exploration and development in Alaska.
- Avalon has agreed to share its extensive geological, geochemical, and geophysical database with New Age Metals (NAM) for 2 years, with the focus being on PGM, PGM Polymetallic, and Rare Metal Projects in Alaska.
- According to the Fraser Institute’s 2017 survey of mining companies, Alaska ranks as the 10th best jurisdiction in the world for mining. In North America it stands as the 6th best mining jurisdiction behind only: Saskatchewan, Nevada, Quebec, Ontario and Arizona.
- NAM has two green metals divisions and its major PGM focus is on the development of its 100% owned River Valley PGM Deposit, the largest undeveloped Primary PGM resource in North America, with 4.62Moz Pd Eq in Measured plus Indicated including an additional 2.7Moz Pd Eq in Inferred (see Mar. 21, 2018). River Valley is situated within 100 KMs of the world class Sudbury metallurgical complex.
April 4th, 2018 / Rockport, ON, Canada – New Age Metals Inc. (TSX.V: NAM; OTCQB: NMTLF; FSE: P7J.F) is pleased to announce that it has signed a binding Letter of Intent (“LOI”) with Avalon Development Corp. (“Avalon”). The LOI calls for an agreement between the companies whereby Avalon will provide acquisition and geological services to New Age Metals (“NAM”) in the state of Alaska. The LOI further defines the extent of the services as follows:
1.To provide NAM with its extensive geological, geochemical, and geophysical database on Platinum Group Metals (PGM’s), PGM Polymetallic, and Rare Metals for a minimum 2 years.
2. Avalon will provide field manager services to NAM in the event any new acquisitions are made as a result of the LOI agreement.
3.Avalon and/or its associated companies will receive finder’s fees and/or property option compensation for its services.
Mr. Harry Barr Chairman/CEO stated: “We are pleased to partner with Avalon Development Corp. and its President Mr. Curt Freeman in Alaska. The LOI accomplishes another milestone in 2018 for NAM which was to find a new mining jurisdiction and a qualified consulting group to help our company continue its search for green metals, PGM’s, and Rare Metals. In the event the company acquires one or more projects in the state of Alaska, we will utilize our Prospector Generator Model, which has been successful in our Lithium Division, and will seek out partners to help us develop our newly acquired projects.”
OPT-IN LIST
If you have not done so already, we encourage you to sign up on our website (www.newagemetals.com) to receive our updated news or click here.
About Avalon development Corp
Since its founding in 1985, Avalon Development has evolved along with the mineral industry and its clients. Avalon exploration teams participated in a number of discoveries in the state. Avalon was responsible for Alaska’s newest gold discovery, the +1 million ounce Peak zone deposit, as well as the 6.5 million ounce intrusive-hosted Dolphin gold deposit, initial targeting of the 20 million ounce Livengood deposit, the southwestern extension of the 1.3 million ounce True North deposit, and deep high grade gold resources at the historic Cleary Hill mine. Avalon has also been responsible for platinum group element, copper-nickel and rare metal discoveries on several exploration projects across Alaska. Avalon continues to work with a number of major and junior mining companies involved in precious, base and strategic metal exploration in Alaska.
ABOUT NAM’S PGM DIVISION
NAM’s flagship project is its 100% owned River Valley PGM Project (NAM Website – River Valley Project) in the Sudbury Mining District of Northern Ontario (100 km east of Sudbury, Ontario). Presently the River Valley Project is North America’s largest undeveloped primary PGM deposit with Measured + Indicated resources of 160 million tones @ 0.44 g/t Palladium, 0.17 g/t Platinum, 0.03 g/t Gold, with a total metal grade of 0.64 g/t at a cut-off grade of 0.4 g/t equating to 3,297,173 ounces PGM plus Gold and 4,626,250 PdEq Ounces. This equates to 4,626,250 PdEq ounces M+I and 2,713,933 PdEq ounces in inferred (figure 1). Having completed a 2018 NI-43-101 resource update the company is finalizing its 2018 exploration programs which will include geophysics, and extensive drill programs, which are all working towards the completion of a Preliminary Economic Assessment (PEA). Our objective is to develop a series of open pits (bulk mining) over the 16 kilometers of mineralization, concentrate on site, and ship the concentrates to the long-established Sudbury Metallurgical Complex.
ABOUT NAM’S LITHIUM DIVISION
The Company has five pegmatite hosted Lithium Projects in the Winnipeg River Pegmatite Field, located in SE Manitoba. Three of the projects are drill ready. This Pegmatite Field hosts the world class Tanco Pegmatite that has been mined for Tantalum, Cesium and Spodumene (one of the primary Lithium ore minerals) in varying capacities, since 1969. NAM’s Lithium Projects are strategically situated in this prolific Pegmatite Field. Presently, NAM is one of the largest mineral claim holders for Lithium in the Winnipeg River Pegmatite Field. On January 15th 2018, NAM announced an agreement with Azincourt Energy Corporation (see Jan 15, 2018 and Feb 22nd, 2018 Press Releases) whereby Azincourt will commit up to $3.85 million dollars in exploration, up to 3 million shares of Azincourt stock to NAM, up to $210,000 in cash, and a 2% net smelter royalty on all 5 projects. Exploration plans for 2018 are currently in progress, whereby a minimum of $500,000 will be expended this year.
QUALIFIED PERSON
The contents contained herein that relate to Exploration Results or Mineral Resources is based on information compiled, reviewed or prepared by Carey Galeschuk, a consulting geoscientist for New Age Metals. Mr. Galeschuk is the Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the technical content of this news release.
On behalf of the Board of Directors
“Harry Barr”
Harry G. Barr
Chairman and CEO
ADDITIONAL INFORMATION
Should you have additional inquiries, please contact Paul Poggione, Corporate Development, Tel: 1-613-659-2773, email: [email protected].
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results and are based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. In addition, forward-looking statements include statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”, “anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”, “prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the Company’s ability and continuation of efforts to timely and completely make available adequate current public information, additional or different regulatory and legal requirements and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the Company on SEDAR (www.sedar.com), including the most recent reports that identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue reliance on forward-looking statements.
Namaste $N.ca Announces Canada’s First Large-Scale National Prospective Observational Study to Observe the Impact of Medical #Cannabis Use for Anxiety Treatment $ACB.ca $HIP.ca $WEED.ca $CMED.ca
Posted by
at 9:51 AM on Wednesday, April 4th, 2018
- Initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants
- One in four Canadians suffer from anxiety and the Company through this study will seek to gain valuable information from study participants on the impact of medical cannabis use in relation to their anxiety
VANCOUVER, British Columbia, April 04, 2018 – Namaste Technologies Inc. (“Namaste†or the “Companyâ€) (CSE:N) (FRANKFURT: M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants. One in four Canadians suffer from anxiety and the Company through this study will seek to gain valuable information from study participants on the impact of medical cannabis use in relation to their anxiety. Namaste is also interested in determining the safety profile of patients using medical cannabis, and whether strain and dose of medical cannabis may impact patient reductions in anxiety ratings. The study will be available to all Canadians and will be conducted under the following conditions:
- Prospective patients must be over 25 years of age.
- Patients must score 8 or above Hospital Anxiety and Depression Scale (HADS).
- The study will span over a 3-month period for each registered patient.
- The study will be submitted for approval to the Veritas Independent Review Board (IRB) prior to commencement.
- The primary investigator in the study is a nurse practitioner.
- Patients can self-refer into the study (without referral through a doctor or specialist).
Namaste plans to offer this study to its patients which are registered under the Company’s wholly-owned subsidiary and virtual patient platform, NamasteMD Inc. (“NamasteMDâ€). Patients suffering from anxiety under the terms outlined above may participate in the study. This study is the first large-scale anxiety study in the nation, establishing Namaste as an innovator in research related to anxiety and cannabis. This is also the first national study where the primary investigator is a nurse practitioner. The Company intends to conduct similar studies in various areas where patients can benefit from the use of medical cannabis. The data collected from the study is valuable for the Company as well as the industry as a whole. The study may be published in peer-reviewed research journals and other medical publications.
For more information on this study please email [email protected]
Management Commentary
Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to have initiated this study with the help of our partners at O-Cannabis. As many people in Canada suffer from varying forms of anxiety, we believe that many of these patients can benefit from the use of medical cannabis instead of prescription pharmaceutical drugs. We hope this study will provide very valuable information for Namaste and for the industry. We encourage qualifying patients to participate and look forward to seeing the results. We plan to undertake additional studies to bring awareness and a better understanding of how medical cannabis can benefit Canadians. We believe that these studies will help Namaste by attracting a larger base of patients and help solidify Namaste’s position as a leader in the Canadian medical cannabis industry.â€
About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.
On behalf of the Board of Directors
“Sean Dollingerâ€
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]
Further information on the Company and its products can be accessed through the links below:
NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca
FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.
Tetra Bio-Pharma $TBP.ca Initiates Enrollment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study $AERO $CBDS $CGRW $APH.ca $GBLX
Posted by
at 8:58 AM on Wednesday, April 4th, 2018
- Announced the initiation of screening and enrollment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain
- Tetra authorized the initiation of the patient enrollment activities at its main clinical site, Santé Cannabis, a private medical cannabis clinic in Montreal which is in compliance with Health Canada Division 5 regulations and the International Conference on Harmonization (ICH) Good Clinical Practices (GCP) (E6) R2
1st Canadian Cannabis Smokable Pellet Study 1st Step Towards Pharmaceutical Distribution of Cannabis
OTTAWA, ONTARIO–(April 4, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced the initiation of screening and enrolment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain.
Tetra authorized the initiation of the patient enrollment activities at its main clinical site, Santé Cannabis, a private medical cannabis clinic in Montreal which is in compliance with Health Canada Division 5 regulations and the International Conference on Harmonization (ICH) Good Clinical Practices (GCP) (E6) R2.
PPP001 aims to be the first smokable cannabis for advanced cancer pain available under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.
“This is a significant milestone in the lead product of our strong pipeline of cannabinoid-based drugs targeting patients with advanced pain,” said Guy Chamberland, Tetra’s CEO and CSO. “The launch of the Phase 3 clinical trial will be used to support the marketing application of PPP001 smokable pellet that is followed by four other cannabinoid-based products that we are developing using different delivery systems such as oral tablets, eye drops, topical ointments and oral capsules of cannabis oil.”
On February 28th, 2018, Santé Cannabis received authorization from the Office of Controlled Substances to use PPP001 (controlled substance) for the Phase 3 clinical trial. This authorization granted the Principal Investigator of the Phase 3 trial, Dr. Antonio Vigano, exemption from the application of several provisions of the Controlled Drugs and Substances Act and the Narcotic Control Regulations thereby allowing the investigator to proceed with the clinical study of PPP001 in advanced cancer patients. In addition, the exemption allows Santé Cannabis to store and dispense the study medication directly to the patients, a process not permitted by Licensed Producers under the ACMPR.
“We are performing the first large study of the safety and efficacy of a dried cannabis smoked drug in advanced cancer patients,” added Guy Chamberland. “Over the next month Tetra will expand the trial by working with other clinics across Canada. Most importantly, we believe this multisite study has the potential to change the current vision of the use of smoked cannabis as an effective palliative care therapy of patients with advanced cancer.”
About PPP001:
PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at:Â www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575
For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556
For investors information, please contact:
[email protected]
(438) 504-5784
#NBA2K League Draft: TV And Stream Info For Wednesday’s Event #Esports $GMBL $KUU.ca
Posted by
at 8:49 AM on Wednesday, April 4th, 2018
Brian Mazique , Contributor Opinions expressed by Forbes Contributors are their own.
If you were wondering how you can watch the first-ever NBA 2K League, here are your answers.
- live pre-draft press conference featuring NBA Commissioner Adam Silver, NBA 2K League Managing Director Brendan Donohue, and Take-Two Interactive Chief Executive Officer Strauss Zelnick
- begins at 12 pm ET and can be seen on NBA TV, the NBA App, NBA.com, and the NBA 2K League Twitter handle.
NBA 2K League Draft Lottery
There will be a live pre-draft press conference featuring NBA Commissioner Adam Silver, NBA 2K League Managing Director Brendan Donohue, and Take-Two Interactive Chief Executive Officer Strauss Zelnick. That begins at 12 pm ET and can be seen on NBA TV, the NBA App, NBA.com, and the NBA 2K League Twitter handle. Silver will announce the league’s first overall pick.
At 1 pm ET, the draft will begin. The entire first round can be seen on NBA TV and the NBA 2K League’s official Twitch channel. The second through sixth rounds will be streamed on Twitch exclusively. There are 17 teams and each will select six players. The draft will progress in a serpentine order until the final pick is announced.
Follow me on Twitter, like my Facebook page and subscribe to my YouTube channel.
Source: https://www.forbes.com/sites/brianmazique/2018/04/04/nba-2k-league-draft-tv-and-stream-info-for-wednesdays-event/#348df2736f93
Could medical #marijuana help curb the #opioid crisis? #MMJ $N.ca $TBP.ca $MCOA
Posted by
at 5:10 PM on Tuesday, April 3rd, 2018
Seriously, There’s Still a 400% Arbitrage Opportunity and it Just Got Less Risky #betterU $BTRU.ca
Posted by
at 3:36 PM on Tuesday, April 3rd, 2018
Seriously, There’s Still a 400% Arbitrage Opportunity and it Just Got Less Risky
- In February we highlighted a very lucrative arbitrage opportunity. At the time of writing, it offered a 435% gain.
- The gist was that this stock was getting a huge cash infusion from investors – and at a massive share price premium. . .
Today – that US$100 million mega deal between BetterU Education Corp. (CVE:BTRU, FRA:5OGA, Mkt Cap: C$43M) and Treasure Union Ltd. (TU) is one step closer to completion.
The Chairman of TUCapital, Kenny Ho, has confirmed that TUCapital has executed on the Subscription Agreement as of April 3rd, 2018. The creation of TUCapital was one of the initiatives highlighted in the final definitive agreement.
BetterU’s Chairman, Tony Keenan, is currently in Guangzhou, China with Mr. Ho coordinating the details of the fund transfer – which is expected to be completed in just 2-3 weeks.
The market may still be iffy as the deal was expected to be completed by March. However, it is important to note deals of this size require the approval of banking institutions and regulators – which ultimately impact the timeline.
This lets contrarian investors take advantage of the crowds’ impatience and doubts.
We also want to mention that Treasure Union Ltd. recently completed a US$50 million Series B funding round with Toronto-based Loraxian Inc., a global renewable energy and infrastructure company. . .
This shows us that Treasure Union has – and is deploying – cash.
We expect in 2-3 weeks BetterU will complete the financing.
At the current price – that’s still 400% upside.
Source: https://mailchi.mp/fe9885407a47/seriously-theres-still-a-400-arbitrage-opportunity-and-it-just-got-less-risky?e=4773499894
Tetra Bio-Pharma $TBP.ca Names Guy Chamberland as Interim CEO $AERO $CBDS $CGRW $APH.ca $GBLX
Posted by
at 2:09 PM on Tuesday, April 3rd, 2018
- Announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO)
- Appointment is effective immediately
OTTAWA, ONTARIO–(April 3, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment is effective immediately.
Dr. Chamberland has been Chief Scientific Officer & Regulatory Affairs of Tetra since June 2016. He has over 23 years’ experience in the development of new drugs in the pharmaceutical industry (Canada and USA). He worked more than 10 years as an executive in various biopharmaceutical companies and was a member of the investment committee of a venture capital fund for 7 years.
Tetra’s former CEO, Bernard Fortier, left the corporation today thereby terminating his role as Chief Executive Officer and member of the Board of Directors.
“We are thankful for Bernard’s contributions to Tetra’s activities,” stated André Rancourt, Chairman of the Board. “Guy’s role as interim CEO will be a tremendous asset at this stage of Tetra’s growth. He will maintain his role and responsibility as Chief Scientific Officer while ensuring the growth and strategic operations of the corporation.”
Chamberland will serve as interim Chief Executive Officer while the Board of Directors conducts a search for a new Chief Executive Officer.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at:Â www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575
For investors information, please contact:
[email protected]
(438) 504-5784
INTERVIEW: Esports Entertainment Group $GMBL Discusses Launch Of VIE.GG, The World’s Safest, Most Secure and Transparent #Esports Wagering Platform $ATVI $TTWO $GAME $EPY.ca
Posted by
at 11:25 AM on Tuesday, April 3rd, 2018
PyroGenesis $PYR.ca to Present at The #MicroCap Conference on April 9th in New York City
Posted by
at 10:20 AM on Tuesday, April 3rd, 2018
- Presenting at this year’s MicroCap Conference on April 9th at 12:00 PM ET at the Essex House in New York City.
- MicroCap Conference provides a unique opportunity to meet one-on-one with management of some of the most attractive companies, network with other like-minded investors
MONTREAL, QC / April 3, 2018 / PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR), (the ”Company,” the ”Corporation” or ”PyroGenesis”) a Company that designs, develops and manufactures plasma waste-to-energy systems and plasma torch systems, announced today that Peter Pascali, CEO & President of PyroGenesis will be presenting at this year’s MicroCap Conference on April 9th at 12:00 PM ET at the Essex House in New York City.
About MicroCap Conference
The MicroCap Conference provides a unique opportunity to meet one-on-one with management of some of the most attractive companies, network with other like-minded investors, and sharpen your skills by learning from our industry panels and expert speakers. This event will bring together over 120 presenting companies across sectors, and north of 600 attendees from the micro-cap investment community.
FOR MORE INFORMATION
Please visit: www.microcapconf.com
Or, contact Tony Yu, CEO at [email protected].
News Compliments of ACCESSWIRE.
About PyroGenesis Canada Inc.
PyroGenesis Canada Inc. is the world leader in the design, development, manufacture and commercialization of advanced plasma processes. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2008 certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.
For further information please contact: Rodayna Kafal, VP, Investor Relations and Strategic Business Development, Phone: (514) 937-0002, E-mail: [email protected].
RELATED LINKS: http://www.pyrogenesis.com/.
SOURCE: PyroGenesis Canada Inc.